James L Speyer

Biosketch / Results /

James L Speyer, M.D.

Professor; Assoc Dir Strategic Planning Net Dev Pub Aff PCC; Assoc Dir Clin Hosp Oper
Departments of Medicine (Perlmutter Cancer Center) and Medicine (Residency Program)
NYU Medical Oncology Associates

Clinical Addresses

160 EAST 34TH STREET, 2 FLOOR
NEW YORK, NY 10016
Hours: Mon. 9 - 5; Tue. 9 - 5; Thu. 9 - 5
Handicap Access: yes
Phone: 212-731-5432
Fax: 212-731-5545

« Back to Results

Medical Specialties

Cancer, Medical Oncology

Medical Expertise

Gynecologic Cancers, Ovarian Cancer, Breast Cancer, Gynecologic Oncology

Insurance

AETNA HMO, AETNA INDEMNITY, AETNA MEDICARE, AETNA POS, AETNA PPO/EPO, AFFINITY, AFFINITY EXCHANGE- ESSENTIAL, Cigna HMO/POS, Cigna PPO, EBCBS EPO, EBCBS HLTHY NY, EBCBS HMO, EBCBS INDEMNITY, EBCBS MEDIBLUE, EBCBS POS, EBCBS PPO, GHI CBP, HEALTHREPUBLIC, HIP ACCESS I, HIP ACCESS II, HIP CHLD HLTH, HIP EPO/PPO, HIP FAM HLTH, HIP HMO, HIP MEDICAID, HIP MEDICARE, HIP POS, MAGNACARE PPO, Medicare, NYS EMPIRE PLAN, OSCAR, OXFORD EXCHANGE, OXFORD FREEDOM, Oxford Liberty, Oxford Medicare, Tricare, UHC COMMUNITY & STATE PLAN, UHC EPO, UHC HMO, UHC POS, UHC PPO, UHC TOP TIER, UNITED EXCHANGE- COMPASS, UPN Elite

Insurance Disclaimer: Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have changed.

« Back to Results

Board Certification

2001 — Ab Internal Medicine (Hematology)
2001 — Ab Internal Medicine - Internal Medicine
2001 — Ab Internal Medicine (Medical Oncology)

Education

1974 — Johns Hopkins University, Medical Education
1974-1976 — Columbia Presbyterian Medical Center (Medicine), Residency Training
1976-1977 — Columbia Presbyterian Medical Center (Hematology), Clinical Fellowships
1977-1979 — National Institute of Health (Oncology), Clinical Fellowships

« Back to Results

Research Interests

ICRF-187.

« Back to Results

All data from NYU Health Sciences Library Faculty Bibliography — -

Contact:
http://hsl.med.nyu.edu/faculty-bibliography-search

Combination of irinotecan and bevacizumab for heavily pretreated recur-rent ovarian cancer: A phase II trial
Ling, H; Muggia, F; Speyer, J; Curtin, J; Blank, S; Boyd, L; Pothuri, B; Li, X; Goldberg, J; Tiersten, A
2013 July 2013;Conference:(44th):e12-, Gynecologic oncology
— id: 452992, year: 2013, vol: Conference:, page: e12, stat: Journal Article,

RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial
Singh, J C; Stein, S; Volm, M; Smith, J A; Adams, S; Meyers, M; Speyer, J L; Novik, Y; Schneider, R; Formenti, S; Muggia, F; Jhaveri, K L; Goldberg, J D; Heese, S; Li, X; Davis, S; Tiersten, A
2013 20 May 2013;31(15):-, Journal of clinical oncology
— id: 452012, year: 2013, vol: 31, page: , stat: Journal Article,

Pathologic response rate in HER2-positive locally advanced breast cancers treated with neoadjuvant trastuzumab and concurrent paclitaxel/radiotherapy
Adams, S; Hochman, T; Huppert, N; Dhage, S; Checka, C; Singh, B; Speyer, J L; Schneider, R; Goldberg, J D; Formenti, S
2012 20 May 2012;30(15):-, Journal of clinical oncology
— id: 249962, year: 2012, vol: 30, page: , stat: Journal Article,

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer
Adams, S; Kozhaya, L; Martiniuk, F; Meng, TC; Chiriboga, L; Liebes, L; Hochman, T; Shuman, N; Axelrod, D; Speyer, JL; Novik, Y; Tiersten, A; Goldberg, JD; Formenti, SC; Bhardwaj, N; Unutmaz, D; Demaria, S
2012 Jul;:6748-6757, Clinical cancer research
— id: 171476, year: 2012, vol: , page: 6748, stat: Journal Article,

Finding ovarian cancer
Hartge, Patricia; Speyer, James L
2012 Jan;104(2):82-83, Journal of the National Cancer Institute
— id: 155934, year: 2012, vol: 104, page: 82, stat: Journal Article,

Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer
Jain, S S; Makeyev, Y G; Muggia, F; Speyer, J L; Curtin, J P; Blank, S V; Boyd, L R; Pothuri, B; Fishman, D; Li, X; Goldberg, J D; Tiersten, A
2012 20 May 2012;30(15):-, Journal of clinical oncology
— id: 250082, year: 2012, vol: 30, page: , stat: Journal Article,

Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer
Singh, J C; Stein, S; Volm, M; Smith, J A; Novik, Y; Speyer, J L; Meyers, M; Adams, S; Omene, C O; Muggia, F; Schneider, R; Formenti, S; Davis, S; Beardslee, B; Tiersten, A
2012 20 May 2012;30(15):-, Journal of clinical oncology
— id: 249952, year: 2012, vol: 30, page: , stat: Journal Article,

Efficacy of RAD001/carboplatin in triple-negative metastatic breast cancer: A phase II study
Singh, J C; Volm, M; Novik, Y; Speyer, J L; Adams, S; Omene, C O; Meyers, M I; Smith, J A; Schneider, R; Formenti, S; Goldberg, J D; Li, X; Davis, S; Beardslee, B; Tiersten, A
2012 20 Sep 2012;30(27):-, Journal of clinical oncology
— id: 395172, year: 2012, vol: 30, page: , stat: Journal Article,

Minimal Acute Toxicity Associated With Concurrent Adjuvant Carboplatin and Accelerated Radiation Therapy for Triple Negative Breast Cancer
Vatner, R.; Fenton-Kerimian, M.; Novik, Y.; Volm, M.; Tiersten, A.; Oratz, R.; Speyer, J.; Formenti, S. C.
2012 NOV 1;84(3 S S):S251-S251, International journal of radiation oncology biology physics
— id: 204692, year: 2012, vol: 84, page: S251, stat: Journal Article,

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies
Seiden, M V; Burris, H A; Matulonis, U; Hall, J B; Armstrong, D K; Speyer, J; Weber, J D A; Muggia, F
2007 Mar;104(3):727-731, Gynecologic oncology
— id: 161235, year: 2007, vol: 104, page: 727, stat: Journal Article,

Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer
Blank, SV; Curtin, JP; Goldman, NA; Runowicz, CD; Speyer, JL; Tiersten, AD; Dancey, J; Wadler, S; Muggia, FM
2006 JUN 20 ;24(18):274S-274S, Journal of clinical oncology
— id: 69299, year: 2006, vol: 24, page: 274S, stat: Journal Article,

Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study
Hochster, Howard S; Plimack, Elizabeth R; Mandeli, John; Wadler, Scott; Runowicz, Carolyn; Goldberg, Gary; Speyer, James; Wallach, Robert; Muggia, Franco
2006 Feb;100(2):324-329, Gynecologic oncology
— id: 62741, year: 2006, vol: 100, page: 324, stat: Journal Article,

Robust control for convection suppression in a fluid layer: The effects of boundary properties, actuator lag, and major parameter uncertainties
Or, A C; Speyer, J L
2006 Apr;73(4 Pt 2):046307-046307, Physical review. E. Statistical, nonlinear, & soft matter physics
— id: 162444, year: 2006, vol: 73, page: 046307, stat: Journal Article,

Gain-scheduled controller for the suppression of convection at high Rayleigh number
Or, A C; Speyer, J L
2005 Apr;71(4 Pt 2):046302-046302, Physical review. E. Statistical, nonlinear, & soft matter physics
— id: 162446, year: 2005, vol: 71, page: 046302, stat: Journal Article,

Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group
Hochster, Howard; Plimack, Elizabeth R; Runowicz, Carolyn D; Speyer, James; Wallach, Robert C; Sorich, Joan; Mandeli, John; Wadler, Scott; Wright, John; Muggia, Franco M
2004 Jan 1;22(1):120-126, Journal of clinical oncology
— id: 42292, year: 2004, vol: 22, page: 120, stat: Journal Article,

A phase I study of carboplatin plus oral topotecan in advanced malignancies
Kim, E; Hochster, H; Novik, Y; Chachoua, A; Speyer, J; Muggia, F
2004 JUL 15 ;22(14):161S-161S, Journal of clinical oncology
— id: 48677, year: 2004, vol: 22, page: 161S, stat: Journal Article,

A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor
Pavlick, Anna C; Chodkiewicz, Catherine; Liebes, Leonard; Hamilton, Anne; Wasserheit, Carolyn; Hochster, Howard; Speyer, James; Phillips, Zoe; Downey, Andrea; Sorich, Joan; Muggia, Franco
2004 Feb;15(2):119-125, Anti-cancer drugs
— id: 44738, year: 2004, vol: 15, page: 119, stat: Journal Article,

Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer
Hochster, Howard; Chachoua, Abraham; Speyer, James; Escalon, Juliette; Zeleniuch-Jacquotte, Anne; Muggia, Franco
2003 Jul 15;21(14):2703-2707, Journal of clinical oncology
— id: 44743, year: 2003, vol: 21, page: 2703, stat: Journal Article,

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer
Jahanzeb, Mohammad; Mortimer, Joanne E; Yunus, Furhan; Irwin, David H; Speyer, James; Koletsky, Alan J; Klein, Paula; Sabir, Tariq; Kronish, Lori
2002 ;7(5):410-417, Oncologist
— id: 44924, year: 2002, vol: 7, page: 410, stat: Journal Article,

Cardiac dysfunction in the trastuzumab clinical experience
Speyer, James
2002 Mar;20(5):1156-1157, Journal of clinical oncology
— id: 162448, year: 2002, vol: 20, page: 1156, stat: Journal Article,

Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival
Rosenberg E; Demopoulos RI; Zeleniuch-Jacquotte A; Yee H; Sorich J; Speyer JL; Newcomb EW
2001 Aug;32(8):808-813, Human pathology
— id: 26681, year: 2001, vol: 32, page: 808, stat: Journal Article,

A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer
Hochster H; Speyer JL; Mandeli JP; Runowicz C; Wadler S; Berk G; Wallach R; Holland JF
1999 Mar;72(3):292-297, Gynecologic oncology
— id: 7986, year: 1999, vol: 72, page: 292, stat: Journal Article,

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group
Hochster H; Wadler S; Runowicz C; Liebes L; Cohen H; Wallach R; Sorich J; Taubes B; Speyer J
1999 Aug;17(8):2553-2561, Journal of clinical oncology
— id: 11932, year: 1999, vol: 17, page: 2553, stat: Journal Article,

Clinical pharmacodynamics of topoisomerase-1 inhibitor therapy: lessons and issues for future studies
Hochster, H; Liebes, L; Wadler, S; Runowicz, C; Potmesil, M; Speyer, J; Muggia, F
1999 NOV ;5(4):3775S-3776S, Clinical cancer research
— id: 53799, year: 1999, vol: 5, page: 3775S, stat: Journal Article,

Doxorubicin-induced cardiomyopathy
Muggia FM; Speyer JL
1999 Feb 25;340(8):654-655, New England journal of medicine
— id: 57059, year: 1999, vol: 340, page: 654, stat: Journal Article,

Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors
Newcomb EW; Sosnow M; Demopoulos RI; Zeleniuch-Jacquotte A; Sorich J; Speyer JL
1999 Jan;154(1):119-125, American journal of pathology
— id: 7414, year: 1999, vol: 154, page: 119, stat: Journal Article,

Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
Sparano JA; Speyer J; Gradishar WJ; Liebes L; Sridhara R; Mendoza S; Fry D; Egorin MJ
1999 Mar;17(3):880-886, Journal of clinical oncology
— id: 7452, year: 1999, vol: 17, page: 880, stat: Journal Article,

Coping with cancer: the impact of the Cancer Information Service on patients and significant others. Part 6
Darrow, S L; Speyer, J; Marcus, A C; Ter Maat, J; Krome, D
1998 ;3 Suppl:86-96, Journal of health communication
— id: 162449, year: 1998, vol: 3 Suppl, page: 86, stat: Journal Article,

PSC833: initial clinical results in refractory ovarian cancer patients
Fields, A; Hochster, H; Runowicz, C; Speyer, J; Goldberg, G; Cohen, C; Dottino, P; Wadler, S; Berk, G; Gretz, H; Mandeli, J; Holland, J; Letvak, L
1998 Aug;10 Suppl 1:S21-S21, Current opinion in oncology
— id: 101803, year: 1998, vol: 10 Suppl 1, page: S21, stat: Journal Article,

Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies
Rosenthal MA; Dennis D; Liebes L; Furmanski P; Caron D; Garrison L; Wiprovnick J; Peace D; Oratz R; Speyer J; Chachoua A
1998 Sep;21(5):371-378, Journal of immunotherapy
— id: 7436, year: 1998, vol: 21, page: 371, stat: Journal Article,

Strategies for reduction of anthracycline cardiac toxicity
Speyer J; Wasserheit C
1998 Oct;25(5):525-537, Seminars in oncology
— id: 12063, year: 1998, vol: 25, page: 525, stat: Journal Article,

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
1997 Aug;3(8):1245-1252, Clinical cancer research
— id: 56951, year: 1997, vol: 3, page: 1245, stat: Journal Article,

Vinorelbine/cisplatin therapy of locally advanced and metastatic breast cancer: an active regimen
Hochster H; Wasserheit C; Siddiqui N; Sorich J; Downey A; Wernz J; Oratz R; Meyers M; Moskovits T; Speyer J
1997 ;16:A606-A606, Proceedings (American Society of Clinical Oncology)
— id: 6028, year: 1997, vol: 16, page: A606, stat: Journal Article,

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
Swain, S M; Whaley, F S; Gerber, M C; Weisberg, S; York, M; Spicer, D; Jones, S E; Wadler, S; Desai, A; Vogel, C; Speyer, J; Mittelman, A; Reddy, S; Pendergrass, K; Velez-Garcia, E; Ewer, M S; Bianchine, J R; Gams, R A
1997 Apr;15(4):1318-1332, Journal of clinical oncology
— id: 162450, year: 1997, vol: 15, page: 1318, stat: Journal Article,

Phase II study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer: a highly active regimen (A NYGOG study)
Hochster H; Speyer J; Wadler S; Runowicz C; Wallach R; Oratz R; Chachoua A; Sorich J; Taubes B; Ludwig E; Broom C; Blum R
1996 ;15:A775-A775, Proceedings (American Society of Clinical Oncology)
— id: 6025, year: 1996, vol: 15, page: A775, stat: Journal Article,

Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer
Runowicz CD; Mandeli J; Speyer JL; Wadler S; Hochster H; Garrison L; Holland JF
1996 Apr;174(4):1151-9; discussion 1159, American journal of obstetrics & gynecology
— id: 35091, year: 1996, vol: 174, page: 1151, stat: Journal Article,

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity [published erratum appears in J Clin Oncol 1996 Dec;14(12):3175]
Wasserheit C; Frazein A; Oratz R; Sorich J; Downey A; Hochster H; Chachoua A; Wernz J; Zeleniuch-Jacquotte A; Blum R; Speyer J
1996 Jul;14(7):1993-1999, Journal of clinical oncology
— id: 7058, year: 1996, vol: 14, page: 1993, stat: Journal Article,

Cardiotoxicity and cardioprotection during chemotherapy
Hochster H; Wasserheit C; Speyer J
1995 Jul;7(4):304-309, Current opinion in oncology
— id: 56822, year: 1995, vol: 7, page: 304, stat: Journal Article,

Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels
Morgan, R J Jr; Speyer, J; Doroshow, J H; Margolin, K; Raschko, J; Sorich, J; Akman, S; Leong, L; Somlo, G; Vasilev, S
1995 Jul;58(1):79-85, Gynecologic oncology
— id: 162451, year: 1995, vol: 58, page: 79, stat: Journal Article,

A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer
Speyer JL; Mandeli J; Hochster H; Runowicz C; Wadler S; Wallach R; Cohen C; Oette D; Sorich J; Demakos E
1995 Mar;56(3):387-394, Gynecologic oncology
— id: 6754, year: 1995, vol: 56, page: 387, stat: Journal Article,

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
1994 Mar;12(3):553-559, Journal of clinical oncology
— id: 6404, year: 1994, vol: 12, page: 553, stat: Journal Article,

PREFACE
MUGGIA, FM; SPEYER, JL
1994 APR ;8(2):R9-&, Hematology-oncology clinics of North America
— id: 52506, year: 1994, vol: 8, page: R9, stat: Journal Article,

Medical: the patient with malignancy
Speyer JL
Family partnership in hospital care: the cooperative care concept New York, NY : Springer Publishing Co., 1994,
— id: 4201, year: 1994, vol: , page: 101, stat: Chapter,

Phase II trial of paclitaxel and cisplatin (DDP) in women with metastatic breast cancer
Wasserheit C; Alter R; Speyer J; Hochster H; Oratz R; Wernz J; Chachoua A; Meyers M; Sorich J; Downey A; et al
1994 ;13:A204-A204, Proceedings (American Society of Clinical Oncology)
— id: 6017, year: 1994, vol: 13, page: A204, stat: Journal Article,

Topotecan 21-day continuous infusion: excellent tolerance of a novel schedule
Hochster H; Speyer J; Oratz R; Meyers M; Wemz J; Chachoua A; Raphael B; Lee R; Sorich J; Taubes B; et al
1993 ;12:A356-A356, Proceedings (American Society of Clinical Oncology)
— id: 6015, year: 1993, vol: 12, page: A356, stat: Journal Article,

Synchronous carcinoma and soft-tissue sarcoma. The importance of searching for incidental radiation exposure
Steinfeld AD; Speyer J
1993 Mar;103(3):970-971, Chest
— id: 13229, year: 1993, vol: 103, page: 970, stat: Journal Article,

Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study
Wadler, S; Beitler, J J; Rubin, J S; Haynes, H; McGill, F; Rozenblit, A; Goldberg, G; Cohen, C; Speyer, J; Runowicz, C
1993 Aug;11(8):1511-1516, Journal of clinical oncology
— id: 162452, year: 1993, vol: 11, page: 1511, stat: Journal Article,

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin
Hochster H; Liebes L; Wadler S; Oratz R; Wernz JC; Meyers M; Green M; Blum RH; Speyer JL
1992 Nov 18;84(22):1725-1730, Journal of the National Cancer Institute
— id: 57431, year: 1992, vol: 84, page: 1725, stat: Journal Article,

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer [published erratum appears in J Clin Oncol 1992 May;10(5):867]
Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M; et al
1992 Jan;10(1):117-127, Journal of clinical oncology
— id: 13730, year: 1992, vol: 10, page: 117, stat: Journal Article,

Intraperitoneal carboplatin: rationale and experience
Speyer JL; Sorich J
1992 Feb;19(1 Suppl 2):107-113, Seminars in oncology
— id: 13706, year: 1992, vol: 19, page: 107, stat: Journal Article,

Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor
Walsh C; Blum RH; Oratz R; Goldenberg A; Downey A; Speyer JL
1992 ;118(1):61-66, Journal of cancer research & clinical oncology
— id: 13725, year: 1992, vol: 118, page: 61, stat: Journal Article,

Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer
Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
1991 May;9(5):809-817, Journal of clinical oncology
— id: 14031, year: 1991, vol: 9, page: 809, stat: Journal Article,

ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies
Green MD; Alderton P; Sobol MM; Gross J; Muggia FM; Speyer JL
1991 ;58(4):101-117, Cancer treatment & research
— id: 35093, year: 1991, vol: 58, page: 101, stat: Journal Article,

Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reduction
Koning J; Palmer P; Franks CR; Mulder DE; Speyer JL; Green MD; Hellmann K
1991 Mar;18(1):1-19, Cancer treatment reviews
— id: 35092, year: 1991, vol: 18, page: 1, stat: Journal Article,

Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine
Muggia FM; Chan KK; Russell C; Colombo N; Speyer JL; Sehgal K; Jeffers S; Sorich J; Leichman L; Beller U; et al
1991 ;28(4):241-250, Cancer chemotherapy & pharmacology
— id: 14203, year: 1991, vol: 28, page: 241, stat: Journal Article,

Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
1991 Jul 15;51(14):3643-3647, Cancer research
— id: 13964, year: 1991, vol: 51, page: 3643, stat: Journal Article,

Survival with regional and distant metastases from cutaneous malignant melanoma
Roses DF; Karp NS; Oratz R; Dubin N; Harris MN; Speyer J; Boyd A; Golomb FM; Ransohoff J; Dugan M; et al.
1991 Apr;172(4):262-268, Surgery, gynecology & obstetrics
— id: 25129, year: 1991, vol: 172, page: 262, stat: Journal Article,

Modulation of the effect of anthracycline efficacy and toxicity by ICRF-187
Blum RH; Walsh C; Green MD; Speyer JL
1990 ;8(2):267-268, Cancer investigation
— id: 35096, year: 1990, vol: 8, page: 267, stat: Journal Article,

Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529)
Green MD; Alderton P; Gross J; Muggia FM; Speyer JL
1990 ;48(1):61-69, Pharmacology & therapeutics
— id: 35095, year: 1990, vol: 48, page: 61, stat: Journal Article,

Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer
Green MD; Speyer JL; Wernz JC; Colombo N; Beller U; Muggia FM; Beckman EM
1990 Aug;8(3):333-336, Investigational new drugs
— id: 15690, year: 1990, vol: 8, page: 333, stat: Journal Article,

Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology
Hochster H; Green M; Liebes L; Speyer JL; Wernz J; Blum R; Muggia F
1990 ;26(4):297-300, Cancer chemotherapy & pharmacology
— id: 35094, year: 1990, vol: 26, page: 297, stat: Journal Article,

Interferon alpha-2a and dacarbazine in melanoma
Kirkwood, J M; Ernstoff, M S; Giuliano, A; Gams, R; Robinson, W A; Costanzi, J; Pouillart, P; Speyer, J; Grimm, M; Spiegel, R
1990 Jun;82(12):1062-1063, Journal of the National Cancer Institute
— id: 162453, year: 1990, vol: 82, page: 1062, stat: Journal Article,

Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial
Oratz R; Speyer JL; Wernz JC; Hochster H; Meyers M; Mischak R; Spitler LE
1990 Aug;9(4):345-354, Journal of biological response modifiers
— id: 15689, year: 1990, vol: 9, page: 345, stat: Journal Article,

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy
Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R; et al
1990 Aug;8(8):1335-1341, Journal of clinical oncology
— id: 15691, year: 1990, vol: 8, page: 1335, stat: Journal Article,

A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer
Speyer JL; Green MD; Sanger J; Zeleniuch-Jacquotte A; Kramer E; Rey M; Wernz JC; Blum RH; Hochester H; Meyers M; et al
1990 Sep;17(2-3):161-163, Cancer treatment reviews
— id: 15688, year: 1990, vol: 17, page: 161, stat: Journal Article,

Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report
Beller U; Chachoua A; Speyer JL; Sorich J; Dugan M; Liebes L; Hayes R; Beckman EM
1989 Sep;34(3):407-412, Gynecologic oncology
— id: 10498, year: 1989, vol: 34, page: 407, stat: Journal Article,

Vaccine immunotherapy of human malignant melanoma
Bystryn JC; Dugan M; Oratz R; Speyer J; Harris MN; Roses DF
Human tumor antigens and specific tumor therapy New York : Liss, 1989,
— id: 2722, year: 1989, vol: , page: 307, stat: Chapter,

Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients
Colombo N; Speyer JL; Green M; Canetta R; Beller U; Wernz JC; Meyers M; Widman T; Blum RH; Piccart M; et al
1989 ;23(5):323-328, Cancer chemotherapy & pharmacology
— id: 10796, year: 1989, vol: 23, page: 323, stat: Journal Article,

Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine
Oratz R; Cockerell C; Speyer JL; Harris M; Roses D; Bystryn JC
1989 Aug;8(4):355-358, Journal of biological response modifiers
— id: 10530, year: 1989, vol: 8, page: 355, stat: Journal Article,

Intraperitoneal cisplatin with i.v. therapy
Speyer JL
1989 ;7(6):613-614, Cancer investigation
— id: 35097, year: 1989, vol: 7, page: 613, stat: Journal Article,

ICRF-187 AND DOXORUBICIN-INDUCED CARDIAC TOXICITY - REPLY
Speyer, JL
1989 Feb 9;320(6):400-400, New England journal of medicine
— id: 31750, year: 1989, vol: 320, page: 400, stat: Journal Article,

Phase I study of the combination of alpha-2 interferon and cisplatinum
Walsh C; Speyer JL; Wernz J; Hochster H; Grossberg H; Chachoua A; Molinaro P; Meyers M; Blum RH
1989 Feb;8(1):11-15, Journal of biological response modifiers
— id: 10721, year: 1989, vol: 8, page: 11, stat: Journal Article,

Immunogenicity of a polyvalent melanoma antigen vaccine in humans
Bystryn JC; Oratz R; Harris MN; Roses DF; Golomb FM; Speyer JL
1988 Mar 15;61(6):1065-1070, Cancer
— id: 16244, year: 1988, vol: 61, page: 1065, stat: Journal Article,

DELAYED TUMOR PROGRESSION IN MELANOMA
DUGAN, M; ORATZ, R; HARRIS, MN; ROSES, DF; SPEYER, J; GOLOMB, F; HENN, M; BYSTRYN, JC
1988 APR ;36(3):A495-A495, Clinical research
— id: 41789, year: 1988, vol: 36, page: A495, stat: Journal Article,

The disposition of carboplatin in ovarian cancer patients
Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
1988 ;22(3):263-270, Cancer chemotherapy & pharmacology
— id: 35098, year: 1988, vol: 22, page: 263, stat: Journal Article,

Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon
Green MD; Speyer JL; Hochster HS; Liebes LF; Dunleavy S; Widman T; Wernz JC; Blum RH; Spiegel RJ; Muggia FM
1988 May 1;48(9):2574-2578, Cancer research
— id: 11108, year: 1988, vol: 48, page: 2574, stat: Journal Article,

Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG Study
Seydel, H G; Leichman, L; Byhardt, R; Cooper, J; Herskovic, A; Libnock, J; Pazdur, R; Speyer, J; Tschan, J
1988 Jan;14(1):33-35, International journal of radiation oncology biology physics
— id: 141402, year: 1988, vol: 14, page: 33, stat: Journal Article,

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer
Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A; et al.
1988 Sep 22;319(12):745-752, New England journal of medicine
— id: 34756, year: 1988, vol: 319, page: 745, stat: Journal Article,

RELATIONSHIP BETWEEN IMMUNE-RESPONSES TO MELANOMA VACCINE IMMUNIZATION AND TUMOR PROGRESSION IN MAN
Dugan, M; Oratz, R; Speyer, J; Roses, DF; Harris, MN; Golomb, F; Bystryn, JC
1987 Apr;35(3):A523-A523, Clinical research
— id: 31370, year: 1987, vol: 35, page: A523, stat: Journal Article,

THE DISPOSITION OF CARBOPLATIN IN OVARIAN-CANCER PATIENTS
Gaver, RC; Colombo, N; Green, MD; George, AM; Deeb, G; Morris, AD; Canetta, RM; Speyer, JL; Farmen, RH; Muggia, FM
1987 Mar;28(3):195-195, Proceedings (American Association for Cancer Research)
— id: 31224, year: 1987, vol: 28, page: 195, stat: Journal Article,

PHASE-I TRIAL AND PHARMACOKINETICS OF ORAL 4 DEMETHOXYDAUN- ORUBICIN (IDARUBICIN)
Green, MD; Hochster, H; Speyer, JL; Liebes, L; Wernz, JC; Blum, RH; Ward, C; London, C; Mendoza, S; Muggia, FM
1987 Mar;28(3):192-192, Proceedings (American Association for Cancer Research)
— id: 31223, year: 1987, vol: 28, page: 192, stat: Journal Article,

A RANDOMIZED TRIAL OF ICRF-187 TO REDUCE DOXORUBICIN (DOX) CARDIOMYOPATHY - COMPARATIVE ACUTE TOXICITIES
Green, MD; Speyer, JL; Stecy, P; Rey, M; Kramer, E; Sanger, J; Ward, C; London, C; Blum, R; Wernz, J; Rohde, J; Muggia, FM
1987 May;5(1):117-117, Investigational new drugs
— id: 31182, year: 1987, vol: 5, page: 117, stat: Journal Article,

A reassessment of the role of second-look laparotomy in advanced ovarian cancer
Ho AG; Beller U; Speyer JL; Colombo N; Wernz J; Beckman EM
1987 Sep;5(9):1316-1321, Journal of clinical oncology
— id: 23744, year: 1987, vol: 5, page: 1316, stat: Journal Article,

Treatment of metastatic malignant melanoma with dacarbazine and cisplatin
Oratz R; Speyer JL; Green M; Blum R; Wernz JC; Muggia FM
1987 Sep;71(9):877-878, Cancer treatment reports
— id: 15693, year: 1987, vol: 71, page: 877, stat: Journal Article,

INDUCTION OF LYMPHOCYTIC CELL INFILTRATE IN HUMAN-MELANOMA NODULES BY ACTIVE IMMUNIZATION TO MELANOMA ANTIGEN VACCINE
Oratz, R; Cockerell, C; Speyer, J; Roses, DF; Harris, MN; Bystryn, JC
1987 Mar;28(3):374-374, Proceedings (American Association for Cancer Research)
— id: 31383, year: 1987, vol: 28, page: 374, stat: Journal Article,

Advanced ovarian cancer: three-year results of a 6-8 month, 2-drug cisplatin-containing regimen
Piccart MJ; Speyer JL; Wernz JC; Noumoff J; Beller U; Beckman M; Dubin N; Demopoulos R; Muggia F
1987 Jun;23(6):631-641, European journal of cancer & clinical oncology
— id: 11393, year: 1987, vol: 23, page: 631, stat: Journal Article,

PHASE-I STUDY OF THE COMBINATION OF ALFA-2 INTERFERON AND CISPLATINUM
Walsh, CM; Speyer, JL; Wernz, JC; Meyers, MI; Widman, T; Grossberg, HS; Spiegel, RJ; Blum, RH
1987 Mar;28(3):231-231, Proceedings (American Association for Cancer Research)
— id: 31225, year: 1987, vol: 28, page: 231, stat: Journal Article,

Can intraperitoneal chemotherapy alter the natural course of ovarian cancer?
Beller U; Beckman EM; Speyer JL
1986 Jun;4(6):1015-1015, Journal of clinical oncology
— id: 35099, year: 1986, vol: 4, page: 1015, stat: Journal Article,

Cisplatin and vinblastine chemotherapy for metastatic non-small cell carcinoma followed by irradiation in patients with regional disease
Blum RH; Cooper J; Schmidt AM; Ashinoff R; Collins A; Wernz JC; Speyer JL; Boyd A; Muggia FM
1986 Mar;70(3):333-337, Cancer treatment reports
— id: 15695, year: 1986, vol: 70, page: 333, stat: Journal Article,

Preparation and characterization of a polyvalent human melanoma antigen vaccine
Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
1986 Jun;5(3):211-224, Journal of biological response modifiers
— id: 16253, year: 1986, vol: 5, page: 211, stat: Journal Article,

CELLULAR IMMUNE-RESPONSE TO A MELANOMA ANTIGEN VACCINE
Bystryn, JC; Oratz, R; Harris, M; Roses, D; Speyer, J
1986 Apr;34(2):A561-A561, Clinical research
— id: 31037, year: 1986, vol: 34, page: A561, stat: Journal Article,

Activity of epirubicin in pancreatic carcinoma
Hochster H; Green MD; Speyer JL; Wernz JC; Blum RH; Muggia FM
1986 Feb;70(2):299-300, Cancer treatment reports
— id: 15696, year: 1986, vol: 70, page: 299, stat: Journal Article,

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial
Hochster HS; Green MD; Blum RH; Wernz JC; Speyer JL; Muggia FM
1986 ;4(3):275-278, Investigational new drugs
— id: 15697, year: 1986, vol: 4, page: 275, stat: Journal Article,

CONCURRENT ADMINISTRATION OF INTERFERON-ALPHA-2 (IFN) AND DOXORUBICIN (DOX)
SPEYER, JL; GREEN, MD; WERNZ, JC; DUNLEAVY, S; BLUM, RH; WIDMAN, T; MUGGIA, FM
1986 MAR ;27(2):182-182, Proceedings (American Association for Cancer Research)
— id: 41428, year: 1986, vol: 27, page: 182, stat: Journal Article,

Prolonged treatment schedules with intraperitoneal 5-fluorouracil diminish the local-regional nature of drug distribution
Sugarbaker PH; Klecker RW; Gianola FJ; Speyer JL
1986 Feb;9(1):1-7, American journal of clinical oncology
— id: 35100, year: 1986, vol: 9, page: 1, stat: Journal Article,

EFFECTS OF A POLYVALENT TUMOR-ANTIGEN VACCINE IN HUMAN- MALIGNANT MELANOMA
Bystryn, JC; Bernstein, P; Harris, M; Roses, D; Speyer, J
1985 ;33(2):A628-A628, Clinical research
— id: 30755, year: 1985, vol: 33, page: A628, stat: Journal Article,

EFFECTS OF A POLYVALENT TUMOR-ANTIGEN VACCINE IN HUMAN- MALIGNANT MELANOMA
Bystryn, JC; Bernstein, P; Harris, M; Roses, D; Speyer, J
1985 ;84(4):338-339, Journal of investigative dermatology
— id: 30767, year: 1985, vol: 84, page: 338, stat: Journal Article,

IMMUNOGENICITY OF A POLYVALENT MELANOMA ANTIGEN VACCINE IN PATIENTS WITH EARLY MELANOMA
Bystryn, JC; Lonberg, M; Bernstein, P; Harris, M; Roses, D; Speyer, J
1985 ;26(MAR):312-312, Proceedings (American Association for Cancer Research)
— id: 30737, year: 1985, vol: 26, page: 312, stat: Journal Article,

Doxorubicin and interferon: rationale and clinical experience
Green, M D; Speyer, J; Wernz, J; Kisner, D; Koeller, J; Blum, R; Von Hoff, D; Muggia, F
1985 Dec;12 Suppl B:61-67, Cancer treatment reviews
— id: 161268, year: 1985, vol: 12 Suppl B, page: 61, stat: Journal Article,

A PHASE-I STUDY OF THE CONCURRENT ADMINISTRATION OF ALPHA-2- INTERFERON AND DOXORUBICIN
Green, MD; Speyer, JL; Wernz, JC; Blum, RH; Dunleavy, S; Widman, T; Muggia, FM
1985 ;33(3):A767-A767, Clinical research
— id: 30846, year: 1985, vol: 33, page: A767, stat: Journal Article,

Single-dose dacarbazine and dactinomycin in advanced malignant melanoma
Hochster H; Levin M; Speyer J; Dunleavy S; Harris M; Roses D; Golomb F; Muggia F
1985 Jan;69(1):39-42, Cancer treatment reports
— id: 25132, year: 1985, vol: 69, page: 39, stat: Journal Article,

4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma
Hochster HS; Green MD; Speyer J; Fazzini E; Blum R; Muggia FM
1985 Nov;3(11):1535-1540, Journal of clinical oncology
— id: 34972, year: 1985, vol: 3, page: 1535, stat: Journal Article,

Ovarian cancer: new therapeutic concepts, renewed optimism
Muggia FM; Piccart MJ; Speyer JL
1985 Nov;103(5):795-797, Annals of internal medicine
— id: 35101, year: 1985, vol: 103, page: 795, stat: Journal Article,

Intraperitoneal chemotherapy: technical experience at five institutions
Piccart MJ; Speyer JL; Markman M; ten Bokkel Huinink WW; Alberts D; Jenkins J; Muggia F
1985 Sep;12(3 Suppl 4):90-96, Seminars in oncology
— id: 35102, year: 1985, vol: 12, page: 90, stat: Journal Article,

A PROSPECTIVE-STUDY OF THE CORRELATION BETWEEN CA-125 SERUM LEVELS AND SURGICALLY VERIFIED TUMOR BURDEN IN OVARIAN-CANCER (OV-CA) PATIENTS (
Piccart, M; Goldhirsch, A; Davis, B; Roesler, H; Muggia, F; Speyer, J
1985 ;26(MAR):148-148, Proceedings (American Association for Cancer Research)
— id: 30894, year: 1985, vol: 26, page: 148, stat: Journal Article,

The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies
Speyer JL
1985 Sep;12(3 Suppl 4):23-28, Seminars in oncology
— id: 35103, year: 1985, vol: 12, page: 23, stat: Journal Article,

Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast
Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
1985 Apr;78(4):555-563, American journal of medicine
— id: 15698, year: 1985, vol: 78, page: 555, stat: Journal Article,

Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer
Sugarbaker PH; Gianola FJ; Speyer JL; Wesley R; Barofsky I; Myers CE
1985 Sep;12(3 Suppl 4):101-111, Seminars in oncology
— id: 35104, year: 1985, vol: 12, page: 101, stat: Journal Article,

TRIAL BASED ON BIOCHEMICAL MODULATION OF 5 FLUOROURACIL (5FU) BY DAILY SEQUENTIAL HYDROXYUREA (HU) IN COLORECTAL-CANCER
Walsh, C; Speyer, JL; Wernz, JC; Blum, RH; Muggia, FM
1985 ;26(MAR):168-168, Proceedings (American Association for Cancer Research)
— id: 30895, year: 1985, vol: 26, page: 168, stat: Journal Article,

IMMUNOGENICITY OF A POLYVALENT MELANOMA TUMOR-ANTIGEN VACCINE IN MAN
BYSTRYN, JC; LEVIN, M; BERNSTEIN, P; SPEYER, J; WOLSK, D
1984 ;25(MAR):229-229, Proceedings (American Association for Cancer Research)
— id: 40806, year: 1984, vol: 25, page: 229, stat: Journal Article,

Cardiotoxicity of anthracyclines
Green MD; Speyer JL; Muggia FM
1984 Feb;20(2):293-296, European journal of cancer & clinical oncology
— id: 35107, year: 1984, vol: 20, page: 293, stat: Journal Article,

Evaluation of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer
Kao AK; Muggia FM; Dubin N; Lerner WA; Stark R; Wernz JC; Speyer JL; Blum RH
1984 Nov;68(11):1383-1385, Cancer treatment reports
— id: 15700, year: 1984, vol: 68, page: 1383, stat: Journal Article,

A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation
Kinsella, T J; Russo, A; Mitchell, J B; Rowland, J; Jenkins, J; Schwade, J; Myers, C E; Collins, J M; Speyer, J; Kornblith, P
1984 Jan;10(1):69-76, International journal of radiation oncology biology physics
— id: 162454, year: 1984, vol: 10, page: 69, stat: Journal Article,

Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer
Ozols RF; Speyer JL; Jenkins J; Myers CE
1984 Oct;68(10):1229-1232, Cancer treatment reports
— id: 35106, year: 1984, vol: 68, page: 1229, stat: Journal Article,

Phase II trial of cyclophosphamide and cis-platinum for non-small cell bronchogenic carcinoma
Schmidt AM; Blum RH; Clayton M; Speyer JL; Bottino J; Muggia FM
1984 Dec;7(6):725-727, American journal of clinical oncology
— id: 35105, year: 1984, vol: 7, page: 725, stat: Journal Article,

Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion
Spiegel RJ; Cooper PR; Blum RH; Speyer JL; McBride D; Mangiardi J
1984 Aug 9;311(6):386-388, New England journal of medicine
— id: 33570, year: 1984, vol: 311, page: 386, stat: Journal Article,

Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols
Greene RF; Collins JM; Jenkins JF; Speyer JL; Myers CE
1983 Jul;43(7):3417-3421, Cancer research
— id: 35108, year: 1983, vol: 43, page: 3417, stat: Journal Article,

A SEQUENTIAL FLUOROURACIL-HYDROXYUREA (5 FU/HU) REGIMEN FOR BOWEL AND PANCREATIC CANCERS
LERNER, WA; MUGGIA, FM; WERNZ, JC; SPEYER, JL; BLUM, RH; SPIEGEL, RJ
1983 ;31(2):A410-A410, Clinical research
— id: 40683, year: 1983, vol: 31, page: A410, stat: Journal Article,

Repeated femoral vein cannulation for administration of chemotherapeutic agents
Nidus BD; Speyer JL; Bottino J; Green M; Levin M; Muggia FM
1983 Feb;67(2):185-186, Cancer treatment reports
— id: 28278, year: 1983, vol: 67, page: 185, stat: Journal Article,

Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
1982 Feb;68(2):227-231, Journal of the National Cancer Institute
— id: 35110, year: 1982, vol: 68, page: 227, stat: Journal Article,

Prolonged infusion chemotherapy with adriamycin (adria) in combination with 5FU and cytoxan (CTX) in an attempt to reduce cardiotoxicity
Green, MD; Speyer, JL; Wernz, J
1982 ;2(3):295-, Breast cancer research & treatment
— id: 579132, year: 1982, vol: 2, page: 295, stat: Journal Article,

Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer
Ozols RF; Young RC; Speyer JL; Sugarbaker PH; Greene R; Jenkins J; Myers CE
1982 Oct;42(10):4265-4269, Cancer research
— id: 35109, year: 1982, vol: 42, page: 4265, stat: Journal Article,

Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule
Spiegel RJ; Blum RH; Levin M; Pinto CA; Wernz JC; Speyer JL; Hoffman KS; Muggia FM
1982 Jan;42(1):354-358, Cancer research
— id: 15704, year: 1982, vol: 42, page: 354, stat: Journal Article,

PHASE-II TRIAL OF DAILY X5 BISANTRENE IN RENAL-CELL CARCINOMA
Spiegel, RJ; Levin, M; Blum, R; Speyer, J; Wernz, J; Pinto, C; Muggia, F
1982 ;23(MAR):111-111, Proceedings of the annual meeting of the American Association for Cancer Research
— id: 30412, year: 1982, vol: 23, page: 111, stat: Journal Article,

Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans
Speyer JL; Sugarbaker PH; Collins JM; Dedrick RL; Klecker RW Jr; Myers CE
1981 May;41(5):1916-1922, Cancer research
— id: 35111, year: 1981, vol: 41, page: 1916, stat: Journal Article,

ADRIAMYCIN (ADM) 24 HOUR INFUSION - A PHASE-I TRIAL
SPEYER, JL; BOTTINO, J; NIDUS, B; BLUM, R; WERNZ, JC; LEVIN, M; HYMES, K; MUGGIA, FM
1981 ;22(MAR):363-363, Proceedings (American Association for Cancer Research)
— id: 40183, year: 1981, vol: 22, page: 363, stat: Journal Article,

Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes
Collins JM; Dedrick RL; King FG; Speyer JL; Myers CE
1980 Aug;28(2):235-246, Clinical pharmacology & therapeutics
— id: 35112, year: 1980, vol: 28, page: 235, stat: Journal Article,

Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally
Speyer JL; Collins JM; Dedrick RL; Brennan MF; Buckpitt AR; Londer H; DeVita VT Jr; Myers CE
1980 Mar;40(3):567-572, Cancer research
— id: 35113, year: 1980, vol: 40, page: 567, stat: Journal Article,

The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies
Speyer JL; Myers CE
1980 ;74(3):264-269, Recent results in cancer research = Fortschritte der Krebsforschung = Progres dans les recherches sur le cancer
— id: 35114, year: 1980, vol: 74, page: 264, stat: Journal Article,

Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics
Dunnick, N R; Jones, R B; Doppman, J L; Speyer, J; Myers, C E
1979 Aug;133(2):221-223, American journal of roentgenology
— id: 162455, year: 1979, vol: 133, page: 221, stat: Journal Article,

Quantitative studies of the specificity of anti-pneumococcal polysaccharide antibodies, types 3 and 8. V. Cross-reacting antibodies in rabbit antisera
Speyer JL; Emans JB; Kimball JW; Pappenheimer AM Jr
1973 Apr;10(4):257-263, Immunochemistry
— id: 35115, year: 1973, vol: 10, page: 257, stat: Journal Article,

Fluorescence depolarization. 3. Selective excitation of contributions from thermally induced intramolecular displacements
Speyer JL; Winkler MH
1969 ;188(2):345-347, Biochimica & biophysica acta
— id: 35116, year: 1969, vol: 188, page: 345, stat: Journal Article,